IRAK4-IN-7
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1) . IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment[1].
Product Specifications
CAS Number
[1801343-74-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
IRAK
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/CA-4948.html
Concentration
10mM
Purity
99.36
Solubility
DMSO : 13.89 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=CC(C2=CC=C(N)N=C2)=N1)NC3=CN=C4C(OC(N5CCOCC5)=N4)=C3
Molecular Formula
C21H19N7O3
Molecular Weight
417.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Venkateshwar Rao GUMMADI, et al. Bicyclic heterocyclyl derivatives as irak4 inhibitors. WO2015104688A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
IRAK4
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Glutamic Pyruvic Transaminase, NT (GPT, Glutamic-pyruvic Transaminase 1, Glutamate Pyruvate Transaminase 1, GPT 1, GPT1, Alanine Aminotransferase 1, AAT1, ALT1, Glutamic-alanine Transaminase 1) (MaxLight 405) discontinued
